Marc D. Grodman, MD, CEO, commented "A year ago this quarter, we were seeing the first signs of the effects of the national and global crisis reflected in our numbers. This year, we are clearly seeing an easing of those pressures. We saw strong improvement in all aspects of our business operations although some of the favorable comparison numbers are probably related to the changing economic effects on a year over year basis. That being said, there have been several strong positives to note for the quarter. Our growth continues to be driven by our esoteric programs: GenPath, Women ™s Health and GeneDx. The clinical business appears to have stabilized and grew this quarter at somewhat higher than historically normal levels. The programs that we have implemented over the past few years to improve cash collection timing have had a positive effect on both DSO and cash flow numbers. These improvements have been the result of systemic improvements and should continue to have an ongoing positive effect."

Dr. Grodman further noted: " It is our firm belief that we have maintained a leadership role in the most exciting areas of laboratory medicine today: Cancer, Genetics and Women ™s Health. We are continuing to expand our Women ™s Health program across the country and to that end we have continued to increase our Women ™s Health sales force. GenPath and GeneDx continue to provide us with dramatic growth opportunities, led by the adoption of new platforms and technologies. We have carefully planned for our growth and have increased both capacity and capacity planning substantially to meet our anticipated needs for the next several quarters. We have several opportunities for growth at this time and we intend to invest in the infrastructure to take advantage of those opportunities. The next few quarters will reflect the effects of these reinvestment plans, but as we have always proven in the past, we believe that the reward will come with continued growth and value to our shareholders."

Dr. Grodman continued: "There is, has been and will continue to be great speculation about the effects of health reform to our industry. While the debate rages on across the country, we are seeing an ongoing need for our services and we believe that our underlying principles will continue to enable us to provide better healthcare through better service and support and regardless of the current debate will enable us to continue to grow and provide industry leadership."

www.bioreference